Moderna, one of the companies behind the ground-breaking mRNA vaccines against COVID-19, has produced proof that its product still works against new variants of the virus, but has plans in place to meet the threat of other variants.
Moderna Takes The Lead With Plan To Tackle New COVID-19 Variants
New Tweaked Booster To Enter Phase I Study
Moderna has unveiled plans to develop a new booster vaccine, tweaked to meet the threat posed by the South African strain.
More from Anti-infective
More from Therapy Areas
• By
The IL-4/IL-13 inhibitor has been approved in the US as the first targeted therapy in over a decade for chronic itching.
• By
The company announced positive topline results for the oral GLP-1 drug in type 2 diabetes that beat expectations.
• By
BriaCell announced its cell therapy Bria-IMT plus checkpoint inhibitors bested Gilead’s Trodelvy in a Phase II trial in HR+ breast cancer; a Phase III trial is enrolling.